Form 4: GeneDx CFO Kevin Feeley Reports RSU Vesting and Tax-Related Stock Sale

GeneDx Holdings Corp.'s Chief Financial Officer, Kevin Feeley, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax withholding obligations.

Summary

• Kevin Feeley, Chief Financial Officer of GeneDx Holdings Corp. (WGS), reported changes in his beneficial ownership of company securities.
• On July 29, 2025, 753 shares of Class A Common Stock were acquired through the vesting of Restricted Stock Units (RSUs) at a price of $0 per share.
• Concurrently, 388 shares of Class A Common Stock were sold at a price of $105.31 per share to satisfy tax withholding obligations related to the RSU vesting.
• This sale was explicitly a "sell to cover" transaction and not a discretionary sale by Mr. Feeley.
• Following these transactions, Mr. Feeley directly owns 3,757 shares of Class A Common Stock.
• Additionally, he beneficially owns RSUs representing contingent rights to receive up to 135,009 shares and options to purchase up to 27,152 shares of Class A Common Stock.
• The RSUs vest with 25% on April 29, 2023, 25% on April 29, 2024, and thereafter 6.25% of the total shares underlying the award vest in equal quarterly installments until fully vested on April 29, 2026, subject to continued service.

Sentiment

Score: 6

Explanation: The filing reports a routine insider transaction involving the vesting of equity compensation and a non-discretionary sale to cover tax obligations. This is a neutral to slightly positive event as it reflects ongoing executive compensation, with the sale not indicating a lack of confidence.

Positives

• The CFO received equity compensation through RSU vesting, aligning his interests with shareholders.
• The sale was a non-discretionary "sell to cover" for tax obligations, which typically does not signal a lack of confidence in the company's future.

Negatives

• A portion of the CFO's shares were sold, reducing his direct equity holding, although this was for tax purposes.

Future Outlook

The filing details future vesting schedules for the CFO's restricted stock units, with remaining shares vesting quarterly until fully vested on April 29, 2026, subject to continued service.

Industry Context

This is a routine insider transaction (equity compensation vesting and tax-related sale) common across all industries for publicly traded companies. It does not provide specific industry-level insights or trends.

Comparison to Industry Standards

• This is a standard "sell to cover" transaction, a common practice for executives receiving equity compensation to manage tax liabilities.
• The transaction aligns with typical corporate governance practices regarding insider stock transactions.
• No specific comparable companies, projects, or results are mentioned in the filing to allow for detailed industry-specific comparison.

Stakeholder Impact

• Shareholders: Minor dilution from RSU vesting (already accounted for in compensation plans) and a small, non-discretionary sale by a key executive. Generally neutral impact.
• Employees: No direct impact mentioned, but reflects standard executive compensation practices.

Next Steps

• Continued vesting of remaining RSUs for Kevin Feeley until April 29, 2026, subject to his continued service to the Issuer.

Key Dates

Recommendation

The filing details a routine 'sell to cover' transaction by the CFO for tax purposes following RSU vesting. This is a non-discretionary sale and does not signal a change in management's confidence or the company's fundamentals. As such, it provides no new information that would warrant a change in investment recommendation based solely on this filing.

Keywords

GeneDx Holdings Corp., WGS, Kevin Feeley, CFO, Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Sale, Sell to Cover, Equity Compensation, Beneficial Ownership